This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Roche. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Journal of neurochemistry, 61(2), 481-489 (1993-08-01)
A single dose of x-irradiation was applied on the cephalic end of newborn rats, and the alterations in the noradrenergic afferents to the cerebellum were studied 180 days later. A net increase in the noradrenaline content of cerebellum was found
The Journal of pharmacology and experimental therapeutics, 265(1), 103-111 (1993-04-01)
The effects of reversible inhibitors of monoamine oxidase-A (moclobemide, Ro 41-1049, both 20 mg/kg, i.p., and brofaromine, 10 mg/kg, i.p.) on the outflow of dopamine (DA) and its metabolites (3,4-dihydroxyphenylacetic acid and homovanillic acid) as well as of 5-hydroxyindoleacetic acid
Ponto-geniculo-occipital (PGO) waves are spontaneously occurring field potentials recorded in the dorsal lateral geniculate nucleus (LGN) just prior to and during rapid eye movement (REM) sleep. Facilitated discharge rates of LGN neurons are associated with PGO waves. In kittens during
Investigational new drugs, 8(2), 145-147 (1990-05-01)
Inhibition of angiogenesis offers an alternative approach to cancer chemotherapy, since solid tumor growth has an absolute dependency on angiogenesis. We have previously shown that 8,9-dihydroxy-7-methyl-benzo [b]quinolizinium bromide (GPA1734) is a basement membrane synthesis inhibitor, and that this compound acts
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
